Post hoc analysis of clinical data from the SCORED trial presented at the American Society of Nephrology Kidney Week 2022 annual scientific meeting, including evidence that:
Sotagliflozin significantly reduced urine albumin-to-creatinine ratio (UACR)
Sotagliflozin had favorable effects on albuminuria progression and regression from a higher UACR category
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.